Uganda - English - National Drug Authority

bkrs pharma pvt. ltd. - paracetamol - parenteral ordinary infusion vials/bottles - 1.0%w/v

Uganda - English - National Drug Authority

bkrs pharma pvt. ltd. - fluconazole - parenteral ordinary infusion vials/bottles - 0.2% w/v

Uganda - English - National Drug Authority

bkrs pharma pvt. ltd. - ofloxacin - parenteral ordinary infusion vials/bottles - 0.2% w/v

Uganda - English - National Drug Authority

bkrs pharma pvt. ltd. - levofloxacin hemihydrate - parenteral ordinary infusion vials/bottles - 500mg

Australia - English - Department of Health (Therapeutic Goods Administration)

ortho development pty ltd -

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - naproxen - tablets - naproxen 500 mg - naproxen - naproxen - - relief of the signs and symptoms of rheumatic diseases including osteoarthritis ankylosing spondylitis of rheumatoid arthritis both in the treatment of acute flares and in the long-term management of the disease. - juvenile rheumatoid arthritis. - periarticular and musculoskeletal disorders - relief of pain in bursitis tendinitis synovitis tenosynovitis and lumbago. - relief of pain swelling tenderness and fever in acute gouty arthritis. - relief of symptoms of primary dysmenorrhea.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - flunitrazepam - tablets - flunitrazepam 2 mg - flunitrazepam - flunitrazepam - insomnia of various etiology.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - carefully consider the potential benefits and risks of naproxen tablets and other treatment options before deciding to use naproxen tablets. use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation) . naproxen as naproxen tablets are indicated: naproxen tablets are contraindicated in the following patients:

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - triamcinolone acetonide, quantity: 10 mg/ml - injection, suspension - excipient ingredients: carmellose sodium; polysorbate 80; benzyl alcohol; sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - intra-articular: kenacort-a 10 injection (sterile triamcinolone acetonide suspension usp) is indicated for intra-articular or intrasynovial administration, and for injections into tendon sheaths, as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis, rheumatoid arthritis, acute and subacute bursitis, acute gouty arthritis, epicondylitis, acute non-specific tenosynovitis, post-traumatic osteoarthritis. intradermal: intralesional administration of kenacort-a 10 injection is indicated for the treatment of keloids, discoid lupus erythermatous, necrobiosis lipoidica diabeticorum, alopecia areata and localised hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus ( neurodermatitis), kenacort-a 10 injection also may be useful in cystic tumours of an aponeurosis or tendon ( ganglia).

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ceftazidime pentahydrate, quantity: 2.328 g (equivalent: ceftazidime, qty 2 g) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime juno is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antibiotics cannot be used. indications include: severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections: for example: otitis media, mastoiditis. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. skin and soft tissue infections: for example, erysipela